Clinical Trial

Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 1, 2023 (before its estimated January 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
This phase II trial studies how well trametinib works in treating patients with hormone-resistant prostate cancer that is growing or getting worse and has spread to other parts of the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2016-08-25; most recent amendment 2023-10-26.
Status change: Active, Not Recruiting → Unknown 2023-10-26
Status change: Recruiting → Active, Not Recruiting 2020-05-08
Status change: Not Yet Recruiting → Recruiting 2018-04-26
Trial Details
NCT Number NCT02881242
Lead Sponsor Jonsson Comprehensive Cancer Center
Collaborators: Stand Up To Cancer, Novartis, Prostate Cancer Foundation
Conditions Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Enrollment 14 participants
Start Date 2018-01-30
Primary Completion 2024-01-31 (estimated)
Study Completion 2025-01-31 (estimated)
Updated on ClinicalTrials.gov 2023-05-01